-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bimatoprost Grenod in Open-Angle Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bimatoprost Grenod in Open-Angle Glaucoma Drug Details: Bimatoprost grenod (NCX-470) is...
-
Product Insights
Ocular Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Hypertension - Drugs In Development, 2023’, provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Open-Angle Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Open-Angle Glaucoma - Drugs In Development, 2023’, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bimatoprost Grenod in Open-Angle Glaucoma Drug Details: Bimatoprost grenod (NCX-470) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mipasetamab Uzoptirine in Osteosarcoma Drug Details:ADCT-601(BGB-601) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimatoprost Grenod in Open-Angle Glaucoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Bimatoprost Grenod in Open-Angle GlaucomaDrug Details: Bimatoprost grenod (NCX-470) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zimberelimab in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zimberelimab in Esophageal Cancer Drug Details:Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that...